Patients get access to Atacand 32mg

Published: 2006-09-19 06:56:00

Updated: 2006-09-19 06:56:00

AstraZeneca Korea said it has marketed Atacand (candesartan cilexetil) 32mg in addition to 4, 8, and 16 mg for an easier administration in patients with hypertension.

Atacand is an angiotensin receptor blocker (ARB), indicated for the treatment of patients with hypertension and patients with c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK